- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 54,34 | +0,59 % | Novonesis (Novozymes A/S): Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% | Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance... ► Artikel lesen | |
| GENMAB | 195,15 | +0,44 % | Genmab A/S: Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | Results from Arm 1 of the EPCORE NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,070 | -0,13 % | Arbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon | 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,450 | 0,00 % | Moleculin Biotech, Inc. - 8-K, Current Report | ||
| VERICEL | 52,50 | -3,67 % | Vericel Corporation: Vericel Reports Third Quarter 2024 Financial Results | Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,414 | -3,50 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,830 | -0,48 % | MustGrow Biologics Corp.: MustGrow Biologics Announces Proposed Private Placement of Units for Approximately $2 Million | Saskatoon, Saskatchewan--(Newsfile Corp. - December 11, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a proposed non-brokered... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,314 | -3,14 % | BioXcel Therapeutics stock hits 52-week low at $0.35 | ||
| REGENXBIO | 7,000 | -4,11 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates | Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this... ► Artikel lesen | |
| AKEBIA | 1,696 | -3,64 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025
Over 300,000 patients, representing approximately 60% of dialysis patient... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,650 | -1,74 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales | ~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 2,940 | -0,68 % | Revance Therapeutics ticks higher as holder says Crown deal undervalues company | ||
| ZEVRA THERAPEUTICS | 8,250 | +1,23 % | Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 | CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 5,010 | +14,51 % | Aktien New York Ausblick: Vorsichtiger Optimismus vor US-Leitzinsentscheidung | NEW YORK (dpa-AFX) - Am US-Aktienmarkt zeichnen sich am Mittwoch zum Handelsstart moderate Gewinne ab. Im Fokus steht die Leitzinsentscheidung zwei Stunden vor Börsenschluss und die begleitenden Kommentare... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 19,000 | +21,79 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment... ► Artikel lesen |
Das Unternehmen BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,835 Euro und damit -1,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.
